Alisertib Alone or with Fulvestrant
Corresponding Organization :
Other organizations : Mayo Clinic, Mayo Clinic in Florida, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Michigan–Ann Arbor, Duke University, Georgetown University, Albert Einstein College of Medicine, Montefiore Medical Center, University of Pennsylvania, Vanderbilt University Medical Center
Variable analysis
- Treatment assignment (arm 1 - alisertib, arm 2 - alisertib and fulvestrant)
- Not explicitly mentioned
- ET resistance (primary vs secondary)
- Central laboratory ERα expression (positive vs negative)
- Prior treatment with CDK 4/6i (yes vs no)
- Not specified
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!